AVTX-002 Shows Promise in Non-Eosinophilic Asthma Trial
Avalo Therapeutics announced topline results from the Phase 2 PEAK trial evaluating AVTX-002 in patients with poorly controlled non-eosinophilic asthma. While the trial did not meet its primary endpoint, AVTX-002 demonstrated a favorable safety and tolerability profile and significantly reduced LIGHT levels for the study duration indicating target engagement. An exploratory analysis revealed a positive trend in reduction of asthma related events in patients treated with AVTX-002 as compared to placebo within a substantial sub-population of patients with elevated baseline LIGHT levels. Additional analyses are ongoing to inform the path forward in asthma and potentially other inflammatory conditions.